Breaking News
A new study demonstrates a way to stop the influenza virus from leaping from one host to the next while continuing to keep the virus from replicating inside the host.
The U.S. Food and Drug Administration has expanded the approved age indication of AREXVY to adults aged 18 to 49 years at increased risk for lower respiratory tract disease caused by RSV.
According to a recent study, adding intravenous methylprednisolone to intravenous immune globulin induction therapy does not significantly increase remission rates among patients with chronic inflammatory demyelinating polyradiculoneuropathy.
BioTrending
- By Amy Scanlin, MS
This revolutionary technology shows promise for addressing a myriad of challenges in medicine, but ethical dilemmas remain.
- By Diane L.M. Cook
Known as liquid gold, human plasma is proving to be a valuable ally in the fight against cancer.
- By Jim Trageser
While still in their early stages of research, FDA has approved more than a dozen complement inhibitors to treat various conditions, and there is hope that more will be on the horizon to treat others.
- By Trudie Mitschang
Virtual hospitals bring hospital-level care directly to patients' homes, representing a transformative step in healthcare delivery.
Awards
BSTQ is an Industry Award-Winning Journal
Since its debut in 2009, BioSupply Trends Quarterly’s articles have been recognized by some of the industry’s most prominent organizations, earning platinum and gold awards.
BSTQ Podcast
Healthcare Marketplace News & Insights
The BioSupply Trends Quarterly (BSTQ) Podcast brings together healthcare professionals, researchers, innovators and advocates to explore the scientific, clinical and operational trends shaping the future of biotherapeutics, healthcare delivery and public health.
